WARF ADVANCES
Top licensing prospects from the University of Wisconsin-Madison
Multimodality Fusion of Medical Data Sources
This system incorporates data from several modalities into machine learning models to generate more accurate diagnostic and prognostic markers for cancer and other diseases.
Read more
Engineered Platelets as Targeted Protein Degraders
UW-Madison researchers have developed an integrative targeted protein degradation (TPD) platform using chemically engineered endogenous platelets.
Read more
Implantable Sensor for Use with Magnetic Resonance Imaging
The implantable microscale inductor-capacitor enhances signal for neuro fMRI images, allowing local tissue conditions to be monitored deep within tissue.
Read more
Novel Photoreceptor-Specific Promoters for Retinal Gene Therapy Applications
This novel photoreceptor specific promoter-enhancer construct is based on two distinct regulatory sequences of the human interphotoreceptor matrix proteoglycan 2 gene (IMPG2).
Read more
Automatic Analysis of Image-Informed Gene Expression Data
UW-Madison researchers have developed a software tool that greatly improves the ability of a clinician to make use of the large amounts of data produced by spatial transcriptomics.
Read more
Metabolomic Biomarkers for Acute Kidney Injury
UW-Madison researchers have identified a panel of metabolites that could be useful indicators of AKI and can be detected much earlier than serum creatinine.
Read more
Read about more licensing prospects!
Featured UW-Madison Researcher
 |
Weiping Tang, Professor of Pharmacy
“Weiping has a great deal of expertise in protein-targeted degraders as well as lysosomal-targeted degraders. We expect these two modalities will be the future of new therapeutics to treat currently untreatable diseases.” – Rafael Diaz, WARF Licensing Manager |
In the News